Universal Beteiligungs und Servicegesellschaft mbH Acquires 3,183 Shares of Charles River Laboratories International, Inc. $CRL
by Doug Wharley · The Cerbat GemUniversal Beteiligungs und Servicegesellschaft mbH grew its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 7.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 48,841 shares of the medical research company’s stock after buying an additional 3,183 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned 0.10% of Charles River Laboratories International worth $9,770,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently made changes to their positions in CRL. PFG Advisors acquired a new position in Charles River Laboratories International during the 4th quarter valued at about $473,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Charles River Laboratories International by 5.6% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,796 shares of the medical research company’s stock worth $2,952,000 after purchasing an additional 782 shares in the last quarter. Asset Management One Co. Ltd. raised its stake in shares of Charles River Laboratories International by 4.0% in the fourth quarter. Asset Management One Co. Ltd. now owns 1,847 shares of the medical research company’s stock worth $375,000 after purchasing an additional 71 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Charles River Laboratories International by 16.8% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,277 shares of the medical research company’s stock valued at $1,651,000 after purchasing an additional 1,192 shares in the last quarter. Finally, CWM LLC lifted its holdings in shares of Charles River Laboratories International by 5.2% in the fourth quarter. CWM LLC now owns 4,305 shares of the medical research company’s stock valued at $859,000 after purchasing an additional 211 shares in the last quarter. 98.91% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
Several brokerages recently issued reports on CRL. Mizuho decreased their price target on Charles River Laboratories International from $215.00 to $175.00 and set a “neutral” rating for the company in a report on Friday, February 20th. Citigroup raised their price objective on Charles River Laboratories International from $200.00 to $265.00 and gave the company a “buy” rating in a research note on Friday, January 16th. Robert W. Baird set a $193.00 target price on shares of Charles River Laboratories International in a research note on Thursday, February 19th. Barclays increased their target price on shares of Charles River Laboratories International from $200.00 to $210.00 and gave the company an “overweight” rating in a report on Tuesday, April 14th. Finally, JPMorgan Chase & Co. dropped their price target on shares of Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating on the stock in a research report on Monday, April 13th. Eleven research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $205.36.
Read Our Latest Stock Analysis on Charles River Laboratories International
Charles River Laboratories International Stock Performance
Shares of Charles River Laboratories International stock opened at $169.90 on Monday. The business’s fifty day simple moving average is $169.24 and its 200 day simple moving average is $183.25. The company has a current ratio of 1.29, a quick ratio of 1.02 and a debt-to-equity ratio of 0.67. Charles River Laboratories International, Inc. has a 12 month low of $112.12 and a 12 month high of $228.88. The firm has a market capitalization of $8.38 billion, a P/E ratio of -57.40, a price-to-earnings-growth ratio of 2.05 and a beta of 1.61.
Charles River Laboratories International (NYSE:CRL – Get Free Report) last announced its quarterly earnings data on Wednesday, February 18th. The medical research company reported $2.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.33 by $0.06. The firm had revenue of $994.23 million during the quarter, compared to the consensus estimate of $986.98 million. Charles River Laboratories International had a positive return on equity of 15.60% and a negative net margin of 3.59%.The business’s revenue for the quarter was down .8% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.66 EPS. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. As a group, analysts anticipate that Charles River Laboratories International, Inc. will post 10.97 EPS for the current year.
About Charles River Laboratories International
Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.
Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.